UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

Nature Medicine, 2019-05, Vol.25 (5), p.751-758

2019

Volltextzugriff (PDF)

The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R

Endocrine-related cancer, 2006-06, Vol.13 (2), p.535-540

2006

Volltextzugriff (PDF)

A template for generic asssessment of tumor response: "myRECIST"

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e14149-e14149

2020

Volltextzugriff (PDF)

Combination treatment of intratumoral vidutolimod (CMP-001), radiosurgery, nivolumab, and ipilimumab for metastatic colorectal carcinoma

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.123-123

2023

Volltextzugriff (PDF)

Nuclear Export Inhibition for Radiosensitization: A Proof-of-Concept Phase 1 Clinical Trial of Selinexor (KPT-330) Combined With Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

International journal of radiation oncology, biology, physics, 2022-10, Vol.114 (2), p.250-255

2022

Volltextzugriff (PDF)

Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase I study, MK3475-223

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.8534-8534

2019

Volltextzugriff (PDF)

Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases

Clinical colorectal cancer, 2023-12, Vol.22 (4), p.442-449.e1

2023

Volltextzugriff (PDF)

Phase II study of olaparib for BRCAness phenotype in pancreatic cancer

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.297-297

2018

Volltextzugriff (PDF)

P1.06-043 A Study to Select Rational Therapeutics in Subjects with Advanced Malignancies (WINTHER) - The Sheba Experience in Lung Cancer Patients

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S692

2017

Volltextzugriff (PDF)

P1.06-043 A Study to Select Rational Therapeutics in Subjects with Advanced Malignancies (WINTHER) - The Sheba Experience in Lung Cancer Patients: Topic: Advanced General

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S692-S692

2017

Volltextzugriff (PDF)

Celiac plexus radiosurgery for pain management in advanced cancer patients: An international phase II trial

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.TPS466-TPS466

2019

Volltextzugriff (PDF)

WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.12011-12011

2018

Volltextzugriff (PDF)

Abstract B30: A phase 1 open label, dose-escalation trial evaluating the safety and tolerability of EF-022, macrophage activator, in subjects with advanced solid malignancies

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B30-B30

2015

Volltextzugriff (PDF)

Abstract CT154: B-cell infiltration in lung cancer predicts response to neoadjuvant pembrolizumab

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT154-CT154

2022

Volltextzugriff (PDF)

WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS11625-TPS11625

2017

Volltextzugriff (PDF)

Nuclear Export Inhibition for Radiosensitization; a Proof-of-Concept Phase I Clinical Trial of Selinexor (KPT-330) Combined with Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

International journal of radiation oncology, biology, physics, 2022-06

2022

Volltextzugriff (PDF)

Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study

Cancer Immunology, Immunotherapy, 2010-10, Vol.59 (10), p.1511-1519

2010

Volltextzugriff (PDF)

A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation

Journal of immunotherapy, 2010-04, Vol.33 (3), p.326-333

2010

Volltextzugriff (PDF)

Improvement of Oxidative Stress Parameters in MDS Patients with Iron Overload Treated with Deferasirox

Blood, 2008-11, Vol.112 (11), p.2675-2675

2008

Volltextzugriff (PDF)

Thymoglobulin ® Rabbit Anti-Thymocyte Globulins (r-ATG) Induces Faster Platelet Recovery and Does Not Suppress Granulocyte Engraftment in a Non-Myeloablative Stem Cell Transplantation Setting

Blood, 2007-11, Vol.110 (11), p.4942-4942

2007

Volltextzugriff (PDF)

Effective Treatment of Resistant Hematological Malignancies by IL-2 Activated NK Cells Using Haploidentically Mismatched Donors by Induction of Graft-Versus-Tumor (GVT) Effect While Avoiding GVHD

Blood, 2005-11, Vol.106 (11), p.5400-5400

2005

Volltextzugriff (PDF)

Duration to Engraftment Requires Significantly Much More Time in Myelodysplastic Syndrome (MDS) Patients as Compared to Acute Myeloid Leukemia (AML) Patients Following Allogeneic Stem Cell Transplantation

Blood, 2005-11, Vol.106 (11), p.5326-5326

2005

Volltextzugriff (PDF)

Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent

Haematologica (Roma), 2005-08, Vol.90 (8), p.1089

2005

Volltextzugriff (PDF)

Treatment of Resistant Leukemia by rIL-2 Activated NK Cells in Recipients of HLA Matched and Haploidentically Mismatched Stem Cell Allografts while Avoiding GVHD

Blood, 2004-11, Vol.104 (11), p.5180-5180

2004

Volltextzugriff (PDF)

Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease

Experimental hematology, 1999-03, Vol.27 (3), p.461-469

1999

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Aktive Filter

ThemaHematology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R

A template for generic asssessment of tumor response: "myRECIST"

Combination treatment of intratumoral vidutolimod (CMP-001), radiosurgery, nivolumab, and ipilimumab for metastatic colorectal carcinoma

Nuclear Export Inhibition for Radiosensitization: A Proof-of-Concept Phase 1 Clinical Trial of Selinexor (KPT-330) Combined With Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase I study, MK3475-223

Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases

Phase II study of olaparib for BRCAness phenotype in pancreatic cancer

P1.06-043 A Study to Select Rational Therapeutics in Subjects with Advanced Malignancies (WINTHER) - The Sheba Experience in Lung Cancer Patients

P1.06-043 A Study to Select Rational Therapeutics in Subjects with Advanced Malignancies (WINTHER) - The Sheba Experience in Lung Cancer Patients: Topic: Advanced General

Celiac plexus radiosurgery for pain management in advanced cancer patients: An international phase II trial

WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies

Abstract B30: A phase 1 open label, dose-escalation trial evaluating the safety and tolerability of EF-022, macrophage activator, in subjects with advanced solid malignancies

Abstract CT154: B-cell infiltration in lung cancer predicts response to neoadjuvant pembrolizumab

WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies

Nuclear Export Inhibition for Radiosensitization; a Proof-of-Concept Phase I Clinical Trial of Selinexor (KPT-330) Combined with Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study

A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation

Improvement of Oxidative Stress Parameters in MDS Patients with Iron Overload Treated with Deferasirox

Thymoglobulin ® Rabbit Anti-Thymocyte Globulins (r-ATG) Induces Faster Platelet Recovery and Does Not Suppress Granulocyte Engraftment in a Non-Myeloablative Stem Cell Transplantation Setting

Effective Treatment of Resistant Hematological Malignancies by IL-2 Activated NK Cells Using Haploidentically Mismatched Donors by Induction of Graft-Versus-Tumor (GVT) Effect While Avoiding GVHD

Duration to Engraftment Requires Significantly Much More Time in Myelodysplastic Syndrome (MDS) Patients as Compared to Acute Myeloid Leukemia (AML) Patients Following Allogeneic Stem Cell Transplantation

Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent

Treatment of Resistant Leukemia by rIL-2 Activated NK Cells in Recipients of HLA Matched and Haploidentically Mismatched Stem Cell Allografts while Avoiding GVHD

Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease

Aktive Filter

Suchergebnisse filtern